Mode
Text Size
Log in / Sign up
N/A Completed N=118 Randomized Triple-blind Treatment

Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease

Sleep Initiation and Maintenance Disorders
Source: ClinicalTrials.gov NCT00946530 ↗
Enrolled (actual)
118
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: Total Sleep Time — 393; 420; 398; 409 units on a scale (minutes)

Summary

The aim of this study is to demonstrate the efficacy of timed exposure to bright light for the treatment of disturbed nighttime sleep and daytime wake in community-dwelling dementia patients and their caregivers, and to determine if there are genetic relationships between memory problems and sleep problems

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Sleep Time
393; 420; 398; 409
SECONDARY
WASO (Wake After Sleep Onset)
124; 107; 63.4; 61.0

Eligibility Criteria

Inclusion Criteria:Alzheimer's Disease Patients:

  • Stanford Alzheimer's Disease Core Center member or potential member, with diagnostic criteria met for probable AD, living with caregiver willing to participate in the protocol
  • Non-institutionalized

Caregivers:

  • Living in home of AD patient and willing to participate in protocol Exclusion Criteria:Alzheimer's Disease Patients:
  • History of manic or bipolar disorder
  • Prior bright light treatment
  • Irregular or non-24 hour sleep/wake cycle
  • Positive result on multi-staged RLS/PLMD
  • Medical/Ophthalmologic Exclusions
  • RDI >20 on overnight EdenTrace® recording

Caregivers:

  • History of manic or bipolar disorder
  • Medical/Ophthalmologic Exclusions
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00946530). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search